Vanguard Group’s Checkpoint Therapeutics CKPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-2,007,910
| Closed | -$8.11M | – | 4284 |
|
|
2025
Q1 | $8.11M | Buy |
2,007,910
+110,477
| +6% | +$368K | ﹤0.01% | 2962 |
|
|
2024
Q4 | $6.07M | Buy |
1,897,433
+523,127
| +38% | +$1.77M | ﹤0.01% | 3188 |
|
|
2024
Q3 | $3.08M | Buy |
1,374,306
+37,324
| +3% | +$86.1K | ﹤0.01% | 3430 |
|
|
2024
Q2 | $2.87M | Buy |
1,336,982
+419,088
| +46% | +$746K | ﹤0.01% | 3456 |
|
|
2024
Q1 | $1.88M | Buy |
917,894
+369,586
| +67% | +$737K | ﹤0.01% | 3613 |
|
|
2023
Q4 | $1.26M | Buy |
548,308
+65,671
| +14% | +$143K | ﹤0.01% | 3749 |
|
|
2023
Q3 | $820K | Buy |
482,637
+94,717
| +24% | +$215K | ﹤0.01% | 3904 |
|
|
2023
Q2 | $958K | Buy |
387,920
+55,953
| +17% | +$153K | ﹤0.01% | 3916 |
|
|
2023
Q1 | $747K | Buy |
331,967
+30,030
| +10% | +$151K | ﹤0.01% | 3996 |
|
|
2022
Q4 | $1.54M | Buy |
301,937
+159
| +0.1% | +$1.15K | ﹤0.01% | 3764 |
|
|
2022
Q3 | $3.14M | Hold |
301,778
| – | – | ﹤0.01% | 3564 |
|
|
2022
Q2 | $3.11M | Hold |
301,778
| – | – | ﹤0.01% | 3610 |
|
|
2022
Q1 | $5.34M | Buy |
301,778
+4,149
| +1% | +$89.1K | ﹤0.01% | 3498 |
|
|
2021
Q4 | $9.26M | Buy |
297,629
+24,868
| +9% | +$823K | ﹤0.01% | 3259 |
|
|
2021
Q3 | $9M | Buy |
272,761
+14,363
| +6% | +$425K | ﹤0.01% | 3304 |
|
|
2021
Q2 | $7.62M | Buy |
258,398
+7,662
| +3% | +$212K | ﹤0.01% | 3355 |
|
|
2021
Q1 | $7.87M | Buy |
250,736
+12,409
| +5% | +$416K | ﹤0.01% | 3286 |
|
|
2020
Q4 | $6.32M | Buy |
238,327
+8,729
| +4% | +$221K | ﹤0.01% | 3244 |
|
|
2020
Q3 | $6.15M | Buy |
229,598
+72,477
| +46% | +$1.74M | ﹤0.01% | 3041 |
|
|
2020
Q2 | $3.11M | Buy |
157,121
+4,707
| +3% | +$85.8K | ﹤0.01% | 3300 |
|
|
2020
Q1 | $2.3M | Buy |
152,414
+4,226
| +3% | +$74.8K | ﹤0.01% | 3267 |
|
|
2019
Q4 | $2.55M | Buy |
148,188
+26,704
| +22% | +$447K | ﹤0.01% | 3377 |
|
|
2019
Q3 | $3.02M | Buy |
121,484
+87
| +0.1% | +$2.39K | ﹤0.01% | 3301 |
|
|
2019
Q2 | $3.68M | Buy |
121,397
+65,583
| +118% | +$2.57M | ﹤0.01% | 3272 |
|
|
2019
Q1 | $1.6M | Buy |
55,814
+5,522
| +11% | +$176K | ﹤0.01% | 3516 |
|
|
2018
Q4 | $916K | Sell |
50,292
-41,234
| -45% | -$982K | ﹤0.01% | 3590 |
|
|
2018
Q3 | $3.28M | Buy |
91,526
+76,266
| +500% | +$2.66M | ﹤0.01% | 3375 |
|
|
2018
Q2 | $455K | Buy |
15,260
+9,065
| +146% | +$313K | ﹤0.01% | 3836 |
|
|
2018
Q1 | $272K | Buy |
+6,195
| New | +$269K | ﹤0.01% | 3911 |
|
Vanguard Group's CKPT Position: Q2 2025 in Review
Vanguard Group sold out of Checkpoint Therapeutics (CKPT) in Q2 2025, closing a stake of 2,007,910 shares — an estimated $8.11M sold.
Vanguard Group first reported a position in CKPT in Q1 2018 and held it in 29 quarters. The position peaked at $9.26M in Q4 2021. 0 funds tracked by Wall St. Rank hold CKPT as of Q2 2025.
- Vanguard Group reported no remaining Checkpoint Therapeutics position as of Q2 2025 after selling out during the quarter.
- Vanguard Group sold 2,007,910 Checkpoint Therapeutics shares in Q2 2025, an estimated $8.11M.
- Vanguard Group first reported a position in Checkpoint Therapeutics in Q1 2018 and held it in 29 quarters.
- Vanguard Group's Checkpoint Therapeutics position peaked at $9.26M in Q4 2021.
- 0 funds tracked by Wall St. Rank held Checkpoint Therapeutics as of Q2 2025.
Based on Vanguard Group's 13F filing for Q2 2025, filed 11 Aug 2025.